“…Many genes associated with reprogramming of cell–cell and cell–extracellular matrix interactions orchestrated by means of the EMT process are differentially expressed in MPM and correlate with worse survival. Interestingly, a substantial number of these genes such as matrix metalloproteases ( MMP3 , MMP7 , and MMP14 ), integrins, and a group of cytoskeletal proteins and cell adhesion molecules ( ITGA3 , ITGB4 , VCAN , VIM , PECAM1 , CDH1 , CDH5 , and CD44 ), structural molecules, and modifiers of ECM ( LOXL2 , BNC1 , GREM-1 , FBN2 , THBS2 , RASGRP3 , ANXA6 , ADAMTS6 , and ADAM19 ) and transcription factors ( SNAI1 , SNAI2 , ZEB1 , TWIST1 , and HMGA2 ) are either significantly enriched in the gene signature or recognized as signaling modulators of the TGF-β (transforming growth factor β) pathway [ 19 , 62 , 112 , 116 , 117 , 118 , 119 , 120 , 121 , 122 ]. Indeed, a large body of evidence that accumulated over the last few years, suggests that the TGF-β signaling pathway is dysregulated in MPM.…”